about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
33.30
-0.20
(-0.60%)
1.8M
XNAS Volume
XNAS 29 May, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bullish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..